LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Criteria Established for Western Blot Diagnosis of Lyme Disease

By LabMedica International staff writers
Posted on 20 Sep 2011
The laboratory diagnosis of Lyme borreliosis (LB) has been dependent mainly on serology with the Western blot test used for confirmation.

To ensure the best use of the Western blot in a routine diagnostic laboratory it is essential that the entire interpretation process remains as simple as possible as a consensus for the interpretation of Western blots to detect Borrelia burgdorferi infection in Europe has been difficult to obtain.

Scientists at the UK National Lyme Borreliosis Testing Service Laboratory, at Raigmore Hospital (Inverness, Scotland) endeavored to interpret what bands are classed as specific, the number of bands needed for a positive result, the role of band intensity combined with clinical information. In 2008, 3,688 patients (4,223 serum samples) were tested by enzyme immunoassay (EIA), with 832 patients tested by confirmatory in-house immunoglobulin IgG Western blot. For a Western blot-positive result, these criteria required at least four bands in total, including the 41 kDa band and a further two specific bands with strong intensity. They found that 272 patients were Western blot-positive, 170 were weak positive, 156 were equivocal, and 234 were negative.

All sera were screened by commercial B. burgdorferi IgM/IgG EIA utilizing B. burgdorferi (B31 strain) antigen produced by Zeus Scientific, (Branchburg, NJ, USA) and the accurate identification of band molecular weight was routinely determined using polyclonal sera obtained from Abcam (Cambridge, UK) and well-categorized Western blot-positive sera. A new interpretation criteria and a testing algorithm were then developed. The revised criteria changed the results in 109/3,688 (3%) patients and produced significantly more Western blot-positive and weak-positive patients than with the current criteria. In total, 76 patients who were negative or equivocal became positive, which may have led to a change in their management. Conversely, 33 patients who were weak-positive became equivocal, but their management may not have been affected.

The most important specific Western blot bands appear to be 20 kDa, 28 kDa, 41 kDa, and 48 kDa, but other maybe as significant. The authors concluded that the revised criteria have simplified blot interpretation and improved the sensitivity and robustness of their Western blot method. Using a protocol tailored to patients that incorporates clinical characteristics means that the entire process will be easier and will aid the management of patients. The study was accepted for publication on August 27, 2011, in the British Journal of Biomedical Science.

Related Links:
UK National Lyme Borreliosis Testing Service
Zeus Scientific
Abcam

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Capillary Blood Collection Tube
IMPROMINI M3

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more